

15 July 2009

The Company Announcements Office
ASX Limited

Neuren Pharmaceuticals Limited Share Purchase Plan

On 10 July 2009 Neuren Pharmaceuticals Limited (Neuren or the Company) announced the main terms of its upcoming Share Purchase Plan (SPP) to shareholders on the basis of regulatory approvals and waiver applications in progress at that time.

The Company has now confirmed that under Australian Securities & Investment Commission Class Order CO 09/425 it can now offer each eligible shareholder with a registered address in Australia or New Zealand up to a maximum of A\$15,000 (rather than up to a maximum of A\$10,000 as previously announced) worth of new fully paid ordinary shares in the capital of the Company at a price of A\$0.03 per share.

The limit of A\$15,000 represents the maximum value of shares that may be issued to a shareholder in a rolling 12 month period. Therefore, any shareholders who subscribed under the Company's previous SPP offer in August 2008 (the August 2008 Offer) will be limited in the amount for which they may subscribe under this SPP to a total of A\$15,000 less the amount subscribed for under the August 2008 Offer.

ASX has also granted the Company a waiver regarding this increase in maximum subscription amount by ASIC to A\$15,000 per annum, which exceeds the relevant ASX Listing Rule exception.

At the time of announcing the SPP terms last week, the Company was able to make an offer of up to A\$15,000 to New Zealand shareholders without providing a disclosure document in accordance with the Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 as amended by Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009.

Yours sincerely



Mr Rob Turnbull
Chief Financial Officer